Coherus Biosciences’ biosimilar Yusimry will have a significantly lower cost tha...
CMS announced that it will cover Eisai's Leqembi, upon a traditional approval, i...
Kisqali administered alongside hormone therapy reduced recurrence by 25% in pati...
The new deal also ensures the EU will have access to the latest versions of futu...
Masitinib has received orphan drug designation from the US Food and Drug Adminis...
The approval comes after Briumvi was approved by the US FDA in December last yea...
The new patent expands coverage for certain ANAVEX 2-73 crystal forms preparatio...
The deal amount includes an initial $107.17m cash consideration and an additiona...
Rentschler’s ATMP site in Stevenage will undertake bioprocess development of AAV...
Funding will be used to support the company’s platform based on Nobel Prize winn...
To clarify the PA role and disambiguate us from physicians, PAs must adopt a new...
As with just about everything else — school, employment, housing, friends — heal...
An insurer backs off from new barriers to colonoscopies, but imposes new incenti...
Algorithms that adjust for race raise the threshold for diagnosing a problem in ...
Why are fake medical devices more lucrative than real ones? Is Ozempic a neurolo...
In the latest edition of STAT's Health Tech newsletter: Nuance's mysterious pric...
